Bodsworth N J, Boag F, Burdge D, Généreux M, Borleffs J C, Evans B A, Modai J, Colebunders R, Thomas M, DeHertogh D, Pacelli L, Thomis J
Sydney Hospital and Taylor Square Private Clinic, Australia.
J Infect Dis. 1997 Jul;176(1):103-11. doi: 10.1086/514011.
The clinical efficacy and safety of sorivudine as treatment for acute cutaneous zoster in human immunodeficiency virus-infected adults was compared with that of acyclovir in a double-blinded randomized study. A total of 125 patients with laboratory-confirmed zoster rash present for < or =72 h were assigned treatment with either 40 mg of sorivudine once daily or 800 mg of acyclovir five times daily, both taken orally for 7 days. Patients were assessed daily until all lesions crusted and then monthly for 6 months for postherpetic neuralgia (PHN) and for 12 months for recurrent or new episodes of zoster. Sorivudine significantly shortened the median period of new vesicle formation from 3.0 to 4.0 days (log rank P = .0001). Sorivudine was effective regardless of duration of rash before treatment. Zoster recurrences and new episodes were experienced by fewer patients assigned sorivudine (11%) than acyclovir (26%, P = .037). No differences were seen in incidence, severity, or duration of either acute neuritis or PHN. Both treatments were well tolerated.
在一项双盲随机研究中，比较了索立夫定与阿昔洛韦治疗人类免疫缺陷病毒感染成人急性带状疱疹的临床疗效和安全性。共有125例实验室确诊的带状疱疹皮疹出现时间≤72小时的患者，被分配接受每日一次40毫克索立夫定或每日五次800毫克阿昔洛韦的治疗，均口服7天。患者每天接受评估，直至所有皮损结痂，然后每月评估6个月以观察带状疱疹后神经痛（PHN）情况，并评估12个月以观察带状疱疹复发或新发作情况。索立夫定显著缩短了新水疱形成的中位时间，从3.0天缩短至4.0天（对数秩检验P = 0.0001）。无论治疗前皮疹持续时间如何，索立夫定均有效。接受索立夫定治疗的患者发生带状疱疹复发和新发作的人数（11%）少于接受阿昔洛韦治疗的患者（26%，P = 0.037）。急性神经炎或PHN的发生率、严重程度或持续时间均无差异。两种治疗的耐受性均良好。
